Tenaya Therapeutics (TNYA) Competitors $1.41 -1.47 (-51.04%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TNYA vs. AVBP, IMTX, REPL, QURE, ETNB, PLRX, RLAY, AVXL, IMNM, and KURAShould you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include ArriVent BioPharma (AVBP), Immatics (IMTX), Replimune Group (REPL), uniQure (QURE), 89bio (ETNB), Pliant Therapeutics (PLRX), Relay Therapeutics (RLAY), Anavex Life Sciences (AVXL), Immunome (IMNM), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry. Tenaya Therapeutics vs. ArriVent BioPharma Immatics Replimune Group uniQure 89bio Pliant Therapeutics Relay Therapeutics Anavex Life Sciences Immunome Kura Oncology ArriVent BioPharma (NASDAQ:AVBP) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, analyst recommendations, earnings and institutional ownership. Do analysts rate AVBP or TNYA? ArriVent BioPharma currently has a consensus target price of $36.80, suggesting a potential upside of 36.70%. Tenaya Therapeutics has a consensus target price of $17.33, suggesting a potential upside of 1,129.31%. Given Tenaya Therapeutics' higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than ArriVent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Tenaya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer AVBP or TNYA? In the previous week, Tenaya Therapeutics had 1 more articles in the media than ArriVent BioPharma. MarketBeat recorded 4 mentions for Tenaya Therapeutics and 3 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.14 beat Tenaya Therapeutics' score of 0.74 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenaya Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, AVBP or TNYA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$69.33MN/AN/ATenaya TherapeuticsN/AN/A-$124.08M-$1.44-0.98 Is AVBP or TNYA more profitable? ArriVent BioPharma's return on equity of -43.89% beat Tenaya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -43.89% -29.67% Tenaya Therapeutics N/A -86.17%-71.14% Do insiders & institutionals have more ownership in AVBP or TNYA? 9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 32.8% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in AVBP or TNYA? Tenaya Therapeutics received 17 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 80.49% of users gave Tenaya Therapeutics an outperform vote. CompanyUnderperformOutperformArriVent BioPharmaOutperform Votes16100.00% Underperform VotesNo VotesTenaya TherapeuticsOutperform Votes3380.49% Underperform Votes819.51% SummaryTenaya Therapeutics beats ArriVent BioPharma on 6 of the 11 factors compared between the two stocks. Ad Porter & CompanyMusk threatens Liberal’s fake “energy crisis”Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNYA vs. The Competition Export to ExcelMetricTenaya TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$111.70M$2.98B$5.11B$9.28BDividend YieldN/A1.85%4.81%4.06%P/E Ratio-0.9846.06134.4517.50Price / SalesN/A410.941,253.71139.58Price / CashN/A182.1340.3137.96Price / Book0.693.914.884.89Net Income-$124.08M-$42.03M$117.66M$225.01M7 Day Performance-60.61%-4.11%14.33%-1.54%1 Month Performance-28.43%6.74%17.31%5.30%1 Year Performance-32.21%21.95%36.11%22.31% Tenaya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNYATenaya Therapeutics4.0248 of 5 stars$1.41-51.0%$17.33+1,129.3%-32.2%$111.70MN/A-0.98110News CoverageGap DownHigh Trading VolumeAVBPArriVent BioPharma1.1598 of 5 stars$26.87+0.6%$36.80+37.0%N/A$905.44MN/A0.0040Short Interest ↑Positive NewsIMTXImmatics1.4373 of 5 stars$7.34+1.8%$16.67+127.1%-26.8%$876.07M$115.50M-10.92260Short Interest ↑REPLReplimune Group4.6169 of 5 stars$12.74+1.5%$17.29+35.7%+45.4%$871.67MN/A-4.11210Positive NewsQUREuniQure3.6313 of 5 stars$17.62+14.4%$32.13+82.3%+99.0%$858.85M$28.59M-3.36500Analyst ForecastETNB89bio1.9374 of 5 stars$7.90+2.7%$30.33+284.0%-24.7%$838.40MN/A-2.6440Short Interest ↑PLRXPliant Therapeutics3.7697 of 5 stars$13.52+1.7%$40.50+199.6%-14.3%$822.69M$1.58M0.0090RLAYRelay Therapeutics2.368 of 5 stars$4.90+4.0%$20.50+318.4%-55.6%$820.16M$25.55M-1.80304AVXLAnavex Life Sciences3.5868 of 5 stars$9.26+9.5%$43.00+364.4%+4.2%$785.25MN/A-18.3640IMNMImmunome2.8032 of 5 stars$12.46-1.0%$28.83+131.4%+59.4%$777.72M$10.13M-1.5540Short Interest ↓Positive NewsKURAKura Oncology4.6109 of 5 stars$9.84+2.2%$29.38+198.5%-20.8%$765.16MN/A-4.08142 Related Companies and Tools Related Companies ArriVent BioPharma Competitors Immatics Competitors Replimune Group Competitors uniQure Competitors 89bio Competitors Pliant Therapeutics Competitors Relay Therapeutics Competitors Anavex Life Sciences Competitors Immunome Competitors Kura Oncology Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TNYA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TNYA Stock Alerts